Sign in
Taking people in United StatesPhase 3

New weekly drug tested for knee arthritis pain in adults with extra weight

Tests a once-weekly drug against placebo for knee arthritis in adults with extra weight.

Key facts

Who runs it
Pfizer
Where
Birmingham, Miami, Shelby, and Tucson, United StatesSee the 4 sites
Registry title
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Status
Recruiting
Phase
Phase 3
People taking part
756 people, planned
Started
26 Oct 2026
Expected to end
30 Oct 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Berobenatide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with painful knee osteoarthritis who are overweight or obese, with or without type 2 diabetes. It compares berobenatide with placebo.

Age
18 years or older, or the minimum age of consent under local rules.
Sex
All sexes can join.
Disease stage
Knee osteoarthritis that meets American College of Rheumatology criteria, with knee pain and a knee X-ray showing Kellgren-Lawrence Grade 2 or 3. Body mass index of at least 27 kg/m². HbA1c below 6.5% (48 mmol/mol) without type 2 diabetes, or from 6.5% to below 10.0% with type 2 diabetes.
Earlier treatment
At least 1 self-reported unsuccessful dietary effort to lose weight. Willing to complete a pain medicine washout. Recent weight-loss medicine, glucose-lowering therapy, or other prohibited treatment, and earlier berobenatide trial participation, are not allowed.
Biomarker or test result
HbA1c at Screening: below 6.5% (48 mmol/mol) without type 2 diabetes; 6.5% (48 mmol/mol) to below 10.0% (86 mmol/mol) with type 2 diabetes.

Main reasons for not taking part

  • Body weight change of more than 5% in the 90 days before Screening
  • Past pancreatitis, active gallbladder disease, or a known stomach-emptying problem
  • Personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Prior or planned knee replacement or planned elective knee surgery
  • Allergy to berobenatide, similar GLP-1 drugs, or any ingredient

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adults 18 years of age or older, or the minimum age of consent according to local regulations
  • Body mass index of at least 27 kg/m² at Screening
  • Currently meets American College of Rheumatology (ACR) Criteria for knee OA
  • Pain due to knee OA
  • Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3
  • Willingness to complete the required analgesic washout
  • History of at least 1 self-reported unsuccessful dietary effort to lose body weight; HbA1c value at Screening of:
  • <6.5% (48 mmol/mol) for participants without T2D
  • ≥6.5% (48 mmol/mol) and <10.0% (86 mmol/mol) for participants with T2D

Who cannot take part

  • Self-reported body weight increase or decrease greater than 5% within 90 days before Screening
  • Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study
  • Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo
  • Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease
  • Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Significant active or unstable psychiatric disorder
  • Condition or knee disorder that could confound assessment of target-knee pain
  • Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient
  • Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment
  • For participants with T2D at Screening only:; Diabetic maculopathy, proliferative diabetic retinopathy, or severe non-proliferative diabetic retinopathy requiring immediate intervention

Where in United States

  • Central Alabama ResearchBirmingham, United StatesTaking people
  • International Research Associates LLCMiami, United StatesNot yet recruiting
  • Carolina Research CenterShelby, United StatesNot yet recruiting
  • Noble Clinical Research, LLCTucson, United StatesNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

The 4 groups in the trial

  • PlaceboPlacebo, for comparison
  • Arm 1: Berobenatide Once WeeklyTreatment being tested

    Berobenatide Once Weekly

    Treatment: Berobenatide

  • Arm 2: Berobenatide Once WeeklyTreatment being tested

    Berobenatide Once Weekly

    Treatment: Berobenatide

  • Arm 3: Berobenatide Once WeeklyTreatment being tested

    Berobenatide Once Weekly

    Treatment: Berobenatide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY WITH OR WITHOUT TYPE 2 DIABETES (VESPER-OA 2)
Plain-language title
New weekly drug tested for knee arthritis pain in adults with extra weightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026